3rd Quarter Financial Results for FYE Mar. 2009 (Consolidated)
January 29, 2009
Exchange where listed: TSE

Name of listed company: TERUMO CORPORATION(URL http://www.terumo.com/): 4543: Akira Takahashi, President: Shouji Hatano, General Manager, Corporate Communication Dept.
: +81 / 3-3217 -6550: February 12, 2009

Company code number
Representative:
Please address all communications toPhone
3rd Qtr. financial statement will be submitted on

1. Consolidated financial highlights for the interim period ended December 2008
(From April 1, 2008 to December 31, 2008)(1) Consolidated financial results
Net sales

Operating income

Ordinary income

Net income(Millions of yen)%

(Millions of yen)%

(Millions of yen)%

(Millions of yen)%

231,526
231,438

12.8

45,52752,44916.0

42,72152,933

14.4

28,74534,752

17.6

Nine months ended December,2008
Nine months ended December,2007

Net income per share, fully
diluted

Net income per share
(Yen)

(Yen)

148.95176.06Nine months ended December,2008
Nine months ended December,2007-(Note) Percentage represent increase (decrease) from the corresponding period in the prior fiscal year.
The amounts shown above ignore values of less than a million yen.
(2) Consolidated financial position
Net assets

Total assets

Capital asset ratio

Net assets per share(Millions of yen)

(Millions of yen)

%

(Yen)

368,801
410,918

269,070
288,86772.9
70.3

1,416.41
1,489.10

December 31, 2008
March 31, 2008

(Note) Shareholders' equity : December 31, 2008: 268,975 million yen, March 31, 2008: 288,780 million yen.
The amounts shown above ignore values of less than a million yen.

2. DividendsＤividends per share
1st quarter 2nd quarter 3rd quarter 4th quarter

Fiscal year ended March 31,2008
Fiscal year ending March 31,2009
Fiscal year ending March 31,2009 (forecast)

total(Yen)

(Yen)

(Yen)

(Yen)

(Yen)

-

14.00
16.00
--

18.00
16.00

32.00
32.00

(Note) Revise of dividends forecast : None

3. Consolidated forecast for the year ending March 2009 (From April 1, 2008 to March 31, 2009)
Operating income

Net sales

Fiscal year ending March, 2009

Net incomeper share

Net income

Ordinary income(Millions of yen)%

(Millions of yen)%

(Millions of yen)%(Millions of yen)%(Yen)

300,000△ 2.153,000△ 20.848,500△ 24.532,500△ 25.1

168.41(Note) Revise of consolidated forecast : Yes(Assumed exchange rate in 4thQ of FY2009: 1US$=87yen, 1Euro=113yen)(Assumed exchange rate of FY2008: 1US$=99yen, 1Euro=141yen)
Percentages represent increase (decrease) from the corresponding period in the prior fiscal year.

14. Consolidated Financial Statements(1) Consolidated Balance Sheets(Millions of yen)
As of December 31,2008
Amount(Assets)
I Current Assets

184,262%
50.0%

As of March 31, 2008
Amount218,072

Cash on hand and in banks

50,04587,343

Trade notes/accounts receivable

70,66869,048Merchandise and finished goods

31,28729,647Work in process

5,969

5,735

Raw material and supplies

15,031

13,356

Deferred income taxes - current

6,177

8,998

Other current assets

5,843

4,744

Allowance for doubtful accounts

(760)

(801)

%
53.1%

II Fixed Assets

184,53950.0%

192,846

46.9%

1. Tangible fixed assets

111,17130.1%

112,744

27.4%

Buildings and structures

41,88044,121

Machinery and transportation equipment31,848

35,602

Land

20,227

20,404

Construction in progress

10,722

6,412

Other tangible fixed assets

6,493

6,202

2. Intangible fixed assets

30,845

8.4%

35,125

Goodwill

26,28230,202Other intangible fixed assets

4,562

4,922

3. Investments and other fixed assets

42,522

11.5%

44,976

Investments in securities

25,19740,527

Deferred income taxes - noncurrent

10,460

1,878

Other assets

6,865

2,570

Total Assets

368,8013

100.0%

410,918

8.6%

10.9%

100.0%

(Millions of yen)
As of December 31,2008
Amount(Liabilities)I Current Liabilities

92,404%25.0%

As of March 31, 2008
Amount114,457

Trade notes/accounts payable

29,04327,245

Short-term bank loans

30,29035,000Accrued income taxes

1,860

17,802

Reserve for employees bonuses

2,250

4,782

Reserve for directors bonuses

142

189

Deferred income taxes - current

198

197

Notes and accounts payable on equipment

7,464

5,646

Other current liabilities

21,154

23,593

II Long-term Liabilities

7,326

Deferred income taxes - noncurrent

7,593

2736

Reserve for retirement allowance
Reserve for retirement benefits for directors
and corporate auditors

3,974

4,263

659728Other long-term liabilities

2,664

2,565

Total Liabilities(Net Assets)
I Shareholders' Equity

II

2.0%

122,05129.7%

295,03280.0%

291,62471.0%

38,716

Capital surplus

59,03059,030Retained earnings

274,082

252,667

Treasury stock(76,797)(58,790)(26,056)

Foreign currency translation adjustments

III Minority Interests
Total Net Assets
Total Liabilities and Net Assets

4

1.8%

27.0%

38,716

Evaluation difference of investment
securities

27.9%

99,731

Capital stockEvaluation Difference and Foreign
Currency Exchange Adjustments%(7.0%)(2,843)(0.7%)(3,766)

5,026(22,290)
94

0.0%(7,869)87

0.0%

269,070

73.0%

288,867

70.3%

368,801

100.0%

410,918

100.0%

(2) Consolidated Statements of Income(Millions of yen)

Nine months ended
December 31, 2008
AmountI Net Sales
II Cost of Sales
Gross Profit on Sales
Selling, General and
III Administrative Expenses

Operating Profit
IV Non-operating Income
Interest income

1,027

Dividend income

418

Royalty income

102

Equity in profit of affiliated companies

61

Other non-operating income

740%

231,526

100.0%

108,05446.7%

123,471

53.3%

77,94433.6%

45,527

19.7%

2,350

1.0%

5,157

2.2%

42,721

18.5%

V Non-operating Expenses
Interest expenses

286

Sales discountForeign exchange losses
Loss on disposal of inventories

413
3,274
243

Other non-operating expenses

939

Ordinary Profit
VI Extraordinary Profit
Gain on sales of fixed assets

17

Gain on sales of securities

80

97

0.0%

129
33

162

0.1%

42,65518.4%

13,8826.0%

280.0%

28,745

12.4%

VII Extraordinary Losses
Loss on disposal of fixed assets
Loss on appraisal of securities

Income Before Taxes
Corporate, Inhabitant and Enterprise Taxes

12,547

Deferred Taxes (reduction)
Minority Interest Income (loss) ofconsolidated companies

1,334

Net Income for the Period4

(3) Consolidated Statements of Cash Flows(Millions of yen)
Nine months ended
December 31, 2008
AmountI

Cash Flows from Operating Activities
Income Before Taxes
Depreciation and amortization
Amortization of goodwill
Equity in profit of affiliated companies
Increase(decrease) in reserve for retirement allowance
Increase(decrease) in reserve for retirement benefits for directors
and corporate auditors
Increase(decrease) in allowance for doubtful accounts
Increase(decrease) in reserve for directors bonuses
Interest and dividend income
Interest expenses
Exchange gain (loss)
Loss on disposal of fixed assets
Gain on sales of fixed assets
Gain on sales of securities
Loss on appraisal of securities
Decrease(increase) in trade receivables
Decrease(increase) in inventories
Increase(decrease) in trade payables
OthersSub-totalInterest and dividends received
Interest paid
Income taxes paid

Cash Flows from Operating Activities

42,655
13,1071,534(61)(263)(68)
32(47)(1,446)286
1,194
129(17)(80)
33(4,680)(7,085)
1,816(7,918)
39,118
1,622(338)(28,769)
11,633

II Cash Flows from Investing Activities
Payments for time deposits with maturities
exceeding 3 months
refund of cash in bank
Capital expenditure
Proceeds from sales of tangible fixed assets
Payments for acquisition of intangible fixed assets
Acquisition of investment in securities
Proceeds from sale of marketable securities
Expense relating to acquisition of newly
consolidated subsidiary

2,983(11,614)
17(820)(32)
580

Cash Flows from Investing Activities(15,612)(3,438)(3,286)

III Cash Flows from financing Activities
Increase(decrease) in short-term bank loan
Buyback of treasury stock
Dividends paid

(4,990)(18,006)(6,593)(29,589)

Cash Flows from Financing Activities
IV Effect of Exchange Rate Changes on Cash andCash Equivalents
V Change in Cash and Cash Equivalents
VI Cash and Cash Equivalents at Beginning of Period
VII Cash and Cash Equivalents at End of Period5(4,022)(37,591)
85,37747,786

5. Segment Information(1) Business Segments(Millions of yen)
Nine months ended
December 31, 2008
AmountOperatingincomeSales
General hospital products
Cardiac & Vascular products
Blood transfusion products
Consumer Home Health Care products
Corporate expenses
Total

113,048
96,246
18,215
4,015
231,526

24,967
26,6352,809
243(9,129)45,527(Note) Main products belonging to each product segment

Product segments

Main products

General hospital products
Disposable medical devices
and Medical electronics

Syringes, Needles, Solution Administrative sets, I.V.catheters, Blood collection tubes,
Electronic medical equipments, etc.

Pharmaceuticals

I.V.solutions, Prefilled syringes, Nutritional products, etc.

CAPD products

Dialysis solutions, etc.

Diabetes care products (Hospital)

Blood glucose monitors, etc.

Home parenteral nutrition and oxygen

Home infusion systems, Home oxygen systems, etc.

Cardiac and Vascular productsInterventional systems

Angiographic catheters, PTCA catheters, Coronary stents, Cerebral aneurysm coils,etc.

Cardiovascular systems

Oxygenarators, Roller pumps, Blood tubing sets, etc.

Vascular grafts

Artificial vascular grafts

Blood transfusion products

Blood bags, Medical electronic equipments for blood collection, etc.

Consumer Health Care Products

Digital Thermometers, Blood pressure monitors, Blood glucose monitors (OTC), etc.

(2) Geographic segments(Millions of yen)
Nine months ended
December 31, 2008
AmountSales to customer

JapanEurope
Americas
Asia and others
Corporate expenses
Total

124,205
42,864
42,12722,328
231,526

Internal sales

36,473
2,989
4,485
11,573(55,521)-(3) Sales results by regions(Millions of yen)
Nine months ended
December 31, 2008
Amount%Japan
124,158
53.6%
Europe42,864
18.5%
Americas42,127
18.2%
Asia and others
22,375
9.7%
Total
231,526
100.0%(Note) Sales in 'Asia and others' includes direct sales from Japan.
6

Operatingincome

41,743
5,638
1,736
5,897
(9,488)45,527Reference information :Consolidated Financial Statements of the previous year
1. Consolidated Statements of Income(Millions of yen)
Nine months ended
December 31, 2007%

AmountNet sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating income
Non-operating income / expenses

231,438

100.0%

103,93144.9%

127,507

55.1%

75,05732.4%

52,44922.7%

483

Ordinary income

52,933Extraordinary income / expenses

22.9%

914

Income before taxes

53,848

Corporate, inhabitant and enterprise taxes

23.3%

19,071

Minority interests

24

Net income for the period

34,75215.0%

2. Consolidated Statements of Cash Flows(Millions of yen)
Nine months ended
December 31, 2007
Cash flows from operating activities

45,668Cash flows from investing activities(23,239)

Cash flows from financing activities

16,434

Effect of exchange rate changes on cash and cash equivalents

8Change in cash and cash equivalents

38,871

Cash and cash equivalents at beginning of period

43,049Cash and cash equivalents at end of period

81,921

73. Segment Information(1) Sales results by product segments(Millions of yen)
Nine months ended
December 31, 2007
Amount%Disposable medical equipments

64,85028.0%

Pharmaceuticals

31,97013.8%

Blood transfusion systems

17,434

7.6%

General hospital products

114,254

49.4%

Catheter systems

57,79725.0%

Cardiovascular systems

28,353

12.2%

Vascular grafts

7,687

3.3%

Cardiac & vascular products

93,83840.5%

CAPD systems

5,429

2.3%

Diabetes care products

10,800

4.7%

Other products

7,116

3.1%

Home health care products

23,34510.1%

Total

231,438

100.0%(Note) Main products belonging to each product segment
Product segments
Disposable medical equipment
Pharmaceuticals

Main products
Syringes, Needles, Solution Administrative sets, I.V.catheters,
Blood collection tubes, Electronic medical devices, etc.
I.V.solutions, Prefilled syringes, Nutritional products, etc.

Cardiovascular systems

Blood bags, Blood transfusion administrative sets, Medical
electronic devices for blood collection, etc.
PTCA dilation catheters, Coronary stents, Guide wires,
Angiographic catheters, Cerebral aneurysm coils, etc.
Roller pumps, Hollow fiber oxygenators, Blood circuits, etc.

Vascular grafts

Artificial vascular grafts

CAPD systems

Dialysis solutions, etc.

Diabetes care products

Blood glucose monitors, etc.

Other productsHome oxygen systems, Digital Thermometers, Electronic
sphygmomanometers, etc.

Blood transfusion systems
Catheter systems(2) Sales results by regions(Millions of yen)
Nine months endedDecember, 2007
Amount%Japan

123,20153.2%

Europe42,254

18.3%

America

43,511

18.8%

Asia and Others

22,471

9.7%

Total

231,438

100.0%

8